Here’s what you need to know.
1. Study co-author Dirk Demuth helped lead a systematic literature review of the drug treatment in more than 7,700 patients with moderate-to-severe UC or CD.
2. The researchers’ data supported previous clinical trial findings on the remission rates and the reductions in disease activity.
Dr. Demuth said the reviewed allowed for a unique perspective into the real-world impact of vedolizumab treatment.
3. Takeda presented two other studies and two abstracts related to the use of vedolizumab.
4. Vedolizumab is approved under the trade name Entyvio. It is the first and only biologic therapy used for the treatment of UC or CD for patients who had an inadequate or quit responding to conventional therapy or tumor necrosis factor-alpha antagonist.
More GI/endoscopy news:
Pure-Vu System effective for intra-procedural colon cleaning: 3 data insights
GI leader to know: Dr. Douglas A. Corley of Kaiser Permanente
MIS approach for liver surgery favorable to open operations: 10 thoughts
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.